I was merely projecting the rate at which they dosed the first 600....if that rate continued it would be 30 months....thanks for clearing that up.

As for the 75% figure, that was something I found on Wiki about Diabetes Mellitus....

The major long-term complications relate to damage to blood vessels. Diabetes doubles the risk of cardiovascular disease[24] and about 75% of deaths in diabetics are due to coronary artery disease.[25] Other "macrovascular" diseases are stroke, and peripheral vascular disease.

I think the biggest milestone event, assuming we reach it and I very much like the chances that we will, is the futility analysis at 125 events. Of course on closer examination that 75% is a mortality figure while the company is defining MACE as stroke, heart attack or death......I was simply trying to get a handle on whether or not, with 600 patients currently dosed....do we have enough participants to reach the futility analysis in just the placebo group....and with your added info Bear it looks to me like we do....hopefully get those on placebo off of it and onto RVX 208.